In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
0:04- Intro
0:34- Fruquintinib and its mechanism of action
1:34- About the FRESCO trial
3:11- FRESCO-2 background
4:22- Findings from the FRESCO-2 study
4:54- What does this approval mean in mCRC?
6:15- Managing toxicities
7:54- Main takeaways
9:04- Looking forward
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, associate professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer (mCRC).
On November 8, 2023, the FDA granted approval to fruquintinib (HMPL-013) for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.1
Dasari explains that fruquintinib is a selective inhibitor of VEGFR-1, -2, and -3. Previously, the agent has inhibited the migration, proliferation, and survival of endothelial cells and also inhibited microvessel formation, tumor cell proliferation, and tumor cell death.
According to Dasari, data from the FRESCO-2 study (NCT04322539) support this regulatory decision. In the phase 3 study, fruquintinib led to a reduction in the risk of death by 34% when given to patients with refractory mCRC. The median overall survival (OS) seen with fruquintinib was 7.4 months compared with 4.8 months with best supportive care in the study. These data represent a significant improvement in OS (HR, 0.66; 95% CI, 0.55-0.80; P < .0001).2,3
In terms of safety, Dasari highlights some of the adverse events observed in the study, including fatigue, hand-foot syndrome, and issues with liver function tests, but notes that they were rare, reflecting the good toxicity profile of the agent.
With this new approval, Dasari looks forward to the future development of fruquintinib beyond its current indication. He hopes to see the agent move into earlier lines of therapy and given in combination with other drugs to build upon its efficacy.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
